NewsOur news NewsBIOVERSYS SUCCESSFULLY COMPLETES PHASE I CLINICAL TRIALS OF BVL-GSK098BioVersys in the NewsSchleichende PandemieNewsBioVersys announces CHF 24.2 million financing to develop AMR clinical pipelineBioVersys in the NewsANTIBIOTICS ARE VICTIMS OF THEIR OWN SUCCESS!NewsBIOVERSYS SUCCESSFULLY COMPLETES THREE PHASE I CLINICAL TRIALS OF BV100BioVersys in the NewsGlobal Research on Antimicrobial Resistance (GRAM) studyNewsBioVersys AG to Present at the H. C. Wainwright BioConnect Virtual ConferenceNewsBioVersys announces first subjects dosed in additional phase 1 clinical trials of BV100NewsBioVersys appoints Dr. William Jenkins a special advisor and board member elect 123…56Next »